Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Goldenwell Biotech (GWLL) Enterprise Value (2019 - 2025)

Goldenwell Biotech (GWLL) has disclosed Enterprise Value for 7 consecutive years, with -$45622.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Enterprise Value fell 859.45% year-over-year to -$45622.0, compared with a TTM value of -$45622.0 through Sep 2025, down 859.45%, and an annual FY2024 reading of -$49404.0, up 7.19% over the prior year.
  • Enterprise Value was -$45622.0 for Q3 2025 at Goldenwell Biotech, up from -$76507.0 in the prior quarter.
  • Across five years, Enterprise Value topped out at -$4755.0 in Q3 2024 and bottomed at -$248569.0 in Q1 2021.
  • Average Enterprise Value over 5 years is -$87931.7, with a median of -$45996.0 recorded in 2022.
  • The sharpest move saw Enterprise Value skyrocketed 82.54% in 2022, then plummeted 859.45% in 2025.
  • Year by year, Enterprise Value stood at -$213556.0 in 2021, then soared by 78.46% to -$45996.0 in 2022, then fell by 15.73% to -$53231.0 in 2023, then rose by 7.19% to -$49404.0 in 2024, then increased by 7.66% to -$45622.0 in 2025.
  • Business Quant data shows Enterprise Value for GWLL at -$45622.0 in Q3 2025, -$76507.0 in Q2 2025, and -$17127.0 in Q1 2025.